Abstract 5528
Background
Amplifications in FGFR1are a potential target to therapy with FGFR inhibitors in squamous cell carcinoma NSCLC (SqCC). Recent insights in other entities demonstrate that the efficacy of these inhibitors is not limited to FGFR1 but affects the whole receptor family. We set out this analysis to identify NSCLC patients with mutations in FGFR2 and/or FGFR3 and to describe clinical and genomic characteristics.
Methods
Within the Network Genomic Medicine Lung Cancer (NGM), all stage IV patients underwent genomic testing using a gene panel consistent of 17 potential oncogenes. The panel was implemented in 2015, and data cut-off for this analysis was July 2018. The panel focuses on point mutations or deletions, i. e., rearrangements or copy-number aberrations were not detectable.
Results
Of 6000 patients analyzed, 26 (0.4%) had an FGFR2 mutation and 21 (0.4%) an FGFR3 mutation. 95% of the detected mutations have not been reported so far. Clinically, both subgroups differed from each other, most strikingly in the clinical presentation: The vast majority of FGFR2 mutations were detected in non-SqCC (76.9%), whereas FGFR3 mutations occurred more commonly in SqCC (57.1%). In the FGFR2 group, more female patients were affected (57.7%), contrasting 71.4% male patients in the FGFR3 group. KRAS mutations co-occurred more frequently in the FGFR2 group (23.1% vs 9.5%) and PIK3CA mutations more frequently in the FGFR3 group (19.0% vs 7.7%). For both groups, most mutations did not affect the kinase domain. Patients with FGFR2 mutation seem to have a favorable outcome as compared to FGFR3 patients (median overall survival not reached vs 8.0 months), but follow-up is still immature (p = 0.201).
Conclusions
Patients with FGFR2 and FGFR3 mutations represent two vastly different subgroups of NSCLC patients. Both mutations are not limited to SqCC and seem to have different prognoses for the outcome of the patients. Further work on the characterization of the different mutations is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Network Genomic Medicine (NGM) Lung Cancer.
Funding
Has not received any funding.
Disclosure
M. Scheffler: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: Mediolanum Biosciences; Honoraria (self): Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Takeda; Advisory / Consultancy: BMS. A. Kron: Advisory / Consultancy: BMS; Advisory / Consultancy: AbbVie; Advisory / Consultancy: Novartis. D.S.Y. Abdulla: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Travel / Accommodation / Expenses: AbbVie. R. Riedel: Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly. S. Michels: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim. R.N. Fischer: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Boehringer Ingelheim. S. Merkelbach-Bruse: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis. R. Büttner: Honoraria (self): Pfizer; Honoraria (self): Novartis. L. Nogova: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD. J. Wolf: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AbbVie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Chugai; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ignyta; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract